- Home
- IBRX vs GENI Comparison
IBRX vs GENI Comparison
Compare IBRX & GENI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- GENI
- Stock Information
- Founded
- IBRX 2014
- GENI 2016
- Country
- IBRX United States
- GENI United Kingdom
- Employees
- IBRX N/A
- GENI N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- GENI Services-Misc. Amusement & Recreation
- Sector
- IBRX Health Care
- GENI Consumer Discretionary
- Exchange
- IBRX Nasdaq
- GENI Nasdaq
- Market Cap
- IBRX 2.4B
- GENI 2.1B
- IPO Year
- IBRX N/A
- GENI N/A
- Fundamental
- Price
- IBRX $2.96
- GENI $10.03
- Analyst Decision
- IBRX Strong Buy
- GENI Strong Buy
- Analyst Count
- IBRX 5
- GENI 12
- Target Price
- IBRX $11.35
- GENI $11.79
- AVG Volume (30 Days)
- IBRX 5.6M
- GENI 4.4M
- Earning Date
- IBRX 03-03-2025
- GENI 05-07-2025
- Dividend Yield
- IBRX N/A
- GENI N/A
- EPS Growth
- IBRX N/A
- GENI N/A
- EPS
- IBRX N/A
- GENI N/A
- Revenue
- IBRX $14,745,000.00
- GENI $510,894,000.00
- Revenue This Year
- IBRX $621.53
- GENI $23.33
- Revenue Next Year
- IBRX $163.57
- GENI $16.38
- P/E Ratio
- IBRX N/A
- GENI N/A
- Revenue Growth
- IBRX 2270.58
- GENI 23.71
- 52 Week Low
- IBRX $2.28
- GENI $4.91
- 52 Week High
- IBRX $10.53
- GENI $11.16
- Technical
- Relative Strength Index (RSI)
- IBRX 49.28
- GENI 52.78
- Support Level
- IBRX $2.69
- GENI $9.53
- Resistance Level
- IBRX $3.47
- GENI $11.16
- Average True Range (ATR)
- IBRX 0.23
- GENI 0.53
- MACD
- IBRX 0.04
- GENI 0.00
- Stochastic Oscillator
- IBRX 35.44
- GENI 49.15
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About GENI Genius Sports Limited
Genius Sports Ltd is a B2B provider of scalable, technology-led products and services to the sports, sports betting, and sports media industries. Its services are organized into three key product areas including Sports Technology and Services; Betting Technology, Content and Services; and Media Technology, Content and Services. All of its products are powered by proprietary technology and robust data infrastructure. It generates maximum revenue from the Betting Technology, Content and Services division. Geographically, the company derives a majority of its revenue from Europe.